Myocardial Infarction News and Research

RSS

Iron in plaque may predict risk of myocardial infarction

Plaque in a heart artery looks threatening, but cardiologists know that many of these buildups will not erupt, dislodge and block a vessel, causing a heart attack that can be fatal. Some will, however, and the challenge is to figure out atherosclerotic plaque that is dangerous and treat or remove it.

16 Nov 2010

Spectrum Pharmaceuticals to present ZEVALIN data at ASH Meeting

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced a total of 11 ZEVALIN related data presentations (five oral, six posters) at the 52nd Annual Meeting of the American Society of Hematology (ASH), being held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

15 Nov 2010

AHA/ASA announce need for comprehensive hospital certification program for heart and stroke care

The American Heart Association should develop a comprehensive hospital certification program with policies and evidence-based criteria for cardiovascular disease and stroke care in the United States, according to an American Heart Association Presidential Advisory published in Circulation: Journal of the American Heart Association.

15 Nov 2010

TCA Cellular Therapy receives QTDP grant for adult stem cell therapies

TCA Cellular Therapy was recently awarded a Qualifying Therapeutic Discovery Program (QTDP) grant from U.S. Department of Health and Human Services. The program was highly competitive with nearly seven thousand applicants vying for funding.

14 Nov 2010

Research roundup: Doctors' industry ties; Patient safety and residents' hours; Designing a medical home

Archives of Internal Medicine: Physician Professionalism And Changes in Physician-Industry Relationships From 2004 to 2009 -"During the last 6 years a number of efforts have aimed to reduce, and in some cases eliminate, certain types of physician-industry relationships (PIRs)," including policies "that forbid physicians from accepting samples and receiving food and beverages in offices, limiting company representatives' access to physicians' offices and clinical areas, and banning faculty participation in speaker bureaus and other forms of promotional activity," write the authors.

12 Nov 2010

Study: Cognitive symptoms of depression cannot be discarded as risk factors for heart disease progression

Cognitive symptoms of depression cannot be simply discarded as risk factors for heart disease progression. When using a structured diagnostic interview, both somatic and cognitive symptoms of depression are associated with adverse cardiac outcome after adjusting for potential confounders.

11 Nov 2010

Hospitals need to work more to prevent heart attack deaths: Study

Door-to-balloon time has dropped dramatically as hospitals rush heart attack patients into treatment, but a five-year study released Monday shows quicker hospital care has not saved more lives.

10 Nov 2010

Angiotech reports $59.0 million total revenue for third quarter 2010

Angiotech Pharmaceuticals, Inc. today announced that it had released its financial results for the third quarter ended September 30, 2010.

9 Nov 2010

Colcrys safe for treating gout flares

Patients who experience gout flares can be treated safely with Colcrys (colchicine, USP), even in the presence of co-morbid conditions that often present physicians with treatment challenges, according to a new analysis presented here at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR).

9 Nov 2010

Limiting inflammation can control accumulation of carotid atherosclerosis in RA patients

New data presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta show that systemic inflammation and rheumatoid arthritis disease activity may contribute to the progression of atherosclerosis in people with RA. The data also show that this progression may be modified favorably by TNF inhibitors and detrimentally by glucocorticoids.

8 Nov 2010

Athersys secures three Therapeutic Discovery Project grants

Athersys, Inc. announced today that it has secured three Therapeutic Discovery Project grants as part of the Patient Protection and Affordable Care Act of 2010. These grants were awarded related to Athersys' development of MultiStem® for the treatment of acute myocardial infarction (AMI), also known as heart attack, and other forms of cardiovascular disease, as well as for the treatment of multiple diseases causing acute tissue damage and chronic inflammation.

4 Nov 2010

APP receives FDA marketing approval for Metoprolol Tartrate Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Metoprolol Tartrate Injection, USP, and expects to launch the medication soon.

30 Oct 2010

IBI receives U.S. patent for novel blood protein biomarkers

Intrinsic Bioprobes today announced that the United States Patents and Trademark Office has issued US Patent 7,816,095 covering novel blood protein biomarkers related to cardiovascular disease. This patent is first of a series of patent applications that cover specific human protein variants as biomarkers with clinical utility.

28 Oct 2010

CYP2C19 gene variant can increase risk of cardiovascular events in patients treated with clopidogrel

An analysis of data from previously published studies indicates that use of the antiplatelet drug clopidogrel for patients who have common genetic variants of a certain gene and are undergoing a procedure such as coronary stent placement have an associated increased risk for major adverse cardiovascular events, particularly development of blood clots in stents, according to a study in the October 27 issue of JAMA.

27 Oct 2010

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).

21 Oct 2010

ACS NSQIP recognizes Christiana Care Health System as participating hospital

The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) has recognized Christiana Care Health System as one of 26 ACS NSQIP participating hospitals in the United States that have achieved exemplary outcomes for surgical patient care.

20 Oct 2010

PCE, NPF form partnership to provide education programs on psoriasis

Practicing Clinicians Exchange (PCE) has formed a partnership with the National Psoriasis Foundation (NPF) to provide continuing education programs to nurse practitioners (NPs) and physician assistants (PAs) throughout the United States.

19 Oct 2010

Proper dosing of beta blockers can save many lives after heart attack

For nearly 40 years a class of drugs known as beta blockers have been proven to increase patients' survival prospects following a heart attack by decreasing the cardiac workload and oxygen demand on the heart. In a breakthrough study released in the American Heart Journal, Northwestern Medicine cardiologist Jeffrey J. Goldberger found the majority of patients are frequently not receiving a large enough dose of these drugs, which can put their recovery from heart attacks and overall health into peril.

15 Oct 2010

Watermelon effective against prehypertension

No matter how you slice it, watermelon has a lot going for it -- sweet, low calorie, high fiber, nutrient rich -- and now, there's more. Evidence from a pilot study led by food scientists at The Florida State University suggests that watermelon can be an effective natural weapon against prehypertension, a precursor to cardiovascular disease.

14 Oct 2010

Tryton Medical enrolls first patient in registry study

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the first patient has been enrolled in E-Tryton Italy, a registry study of the company's Tryton Side Branch Stent System.

12 Oct 2010